Skip to content

Life Sciences

ISSN 1879-0631, 0024-3205

42 papers in the library · 1,793 citations · publishing 1982-2023

Papers

Sort Most recent Most cited

Chronic Δ9-tetrahydrocannabinol treatment has dose-dependent effects on open field exploratory behavior and [3H] SR141716A receptor binding in the rat brain.

Life Sciences August 15, 2023 Lily Freeman-Striegel, John Hamilton, Renuka Kannappan et al.

Acute and chronic Δ9-THC exposure paradigms affect the body differently. More must be known about the impact of chronic Δ9-THC on cannabinoid-1 (CB1R) and mu-opioid (MOR) receptor levels in the brain. The present study examined chronic Δ9-THC's effects on CB1R and MOR levels and locomotor activity. Adolescent Sprague-Dawley rats were given daily intraperitoneal injections of Δ9-THC [0.75mg/kg...

Dopaminergic neurotoxic effects of 3-TFMPP derivatives.

Life Sciences September 15, 2018 Mohammed Majrashi, Mohammed Almaghrabi, Maali Fadan et al.

Designer drugs are synthetically formulated to mimic the psychostimulatory effects of an original controlled/illegal drug of abuse. Designer drugs have similar chemical structure or functional analog as compared to existing controlled psychostimulatory drugs. There is a substantial rise in the production and use of designer drugs globally. Piperazine designer drugs were synthesized as an...

DOI: 10.1016/j.lfs.2018.07.052 (opens in new tab) Full text (opens in new tab) Designer drugs Dopamine Mechanisms of toxicity Neurotoxicity +2

How much alcohol is in ketamine's antidepressant action?

Life Sciences January 1, 2017 Udo Bonnet

Ketamine is approved to start and maintain anaesthesia or analgesia. Ketamine is also known to be neurotoxic and an old drug of abuse. Numerous studies have proven a rapid and strong antidepressant response (AR) following parenteral sub-anaesthetic ketamine doses when applied the first time to patients with treatment resistant unipolar or bipolar major depression. This rapid and robust AR is...

Elucidating the neurotoxic effects of MDMA and its analogs.

Life Sciences April 17, 2014 Senthilkumar S Karuppagounder, Dwipayan Bhattacharya, Manuj Ahuja et al.

There is a rapid increase in the use of methylenedioxymethamphetamine (MDMA) and its structural congeners/analogs globally. MDMA and MDMA-analogs have been synthesized illegally in furtive dwellings and are abused due to its addictive potential. Furthermore, MDMA and MDMA-analogs have shown to have induced several adverse effects. Hence, understanding the mechanisms mediating this neurotoxic...

DOI: 10.1016/j.lfs.2014.02.010 (opens in new tab) Full text (opens in new tab) Drugs of abuse MDMA & Analogs Mitochondrial dysfunction Neurotoxicity +1

Bath salts and synthetic cathinones: an emerging designer drug phenomenon.

Life Sciences February 27, 2014 Christopher L German, Annette E Fleckenstein, Glen R. Hanson

Synthetic cathinones are an emerging class of designer drugs abused for psychostimulant and hallucinogenic effects similar to cocaine, methylenedioxymethamphetamine (MDMA), or other amphetamines. Abuse of synthetic cathinones, frequently included in products sold as 'bath salts', became prevalent in early 2009, leading to legislative classification throughout Europe in 2010 and schedule I...

Psychopharmacology of the hallucinogenic sage Salvia divinorum.

Life Sciences December 22, 2005 Thomas E Prisinzano 128 citations

At present, the Mexican mint Salvia divinorum is an unregulated hallucinogen. This has resulted in various on-line botanical companies advertising and selling S. divinorum as a legal alternative to other regulated plant hallucinogens. It is predictable that its misuse will increase rapidly. The active ingredient in S. divinorum is the neoclerodane diterpene, salvinorin A (1a), which has been...

Screening the receptorome for plant-based psychoactive compounds.

Life Sciences December 22, 2005 Kerry Ann O'Connor, Bryan L. Roth 22 citations

Throughout time, humans have used psychoactive plants and plant-derived products for spiritual, therapeutic and recreational purposes. Furthermore, the investigation of psychoactive plants such as Cannabis sativa (marijuana), Nicotiana tabacum (tobacco) and analogues of psychoactive plant derivatives such as lysergic acid diethylamide (LSD) have provided insight into our understanding of...

DOI: 10.1016/j.lfs.2005.09.002 (opens in new tab) Full text (opens in new tab) Plant compounds Natural compounds Plant-derived substances Phytochemicals +16

Endocannabinoid lipids and mediated system: implications for alcoholism and neuropsychiatric disorders.

Life Sciences August 19, 2005 K Yaragudri Vinod, Basalingappa L Hungund

Several natural lipids have emerged as candidate modulators of central nervous system (CNS) functions. Fatty acid amides and their coupled signaling pathways are known to regulate several physiological and behavioral processes. Recent studies from our laboratory and others also have implicated endogenous marijuana-like brain constituents, endocannabinoids (ECs), and cannabinoid-1 (CB1)...

Role of lipids and lipid signaling in the development of cannabinoid tolerance.

Life Sciences August 19, 2005 Billy R Martin

Cannabinoid agonists such as Delta9-tetrahydrocannabinol (THC) produce a wide range of pharmacological effects both in the central nervous system and in the periphery. One of the most striking features of cannabinoids such as THC is the magnitude to tolerance that can be produced upon repetitive administration of this substance to animals. Relatively modest dosing regimens are capable of...

Salvinorin A: a novel and highly selective kappa-opioid receptor agonist.

Life Sciences October 15, 2004 Feng Yan, Bryan L. Roth 68 citations

kappa-opioid receptors (KORs) represent the principal site of action of dynorphin and related neuropeptides. Recently, Salvinorin A--a naturally occurring neoclerodane diterpene hallucinogen was identified to be a highly selective KOR agonist. In this brief review we summarize the known chemistry, pharmacology and biology of salvinorin A. Because salvinorin A profoundly alters human...

Multiple molecular and neuropharmacological effects of MDMA (Ecstasy).

Life Sciences January 2, 2004 Rabi Simantov

3,4-Methylenedioxymethamphetamine (MDMA), commonly referred to as Ecstasy, is a widely abused, psychoactive recreational drug, which induces short- and long-term neuropsychiatric behaviors. This drug is neurotoxic to serotonergic neurons in vivo, and induces programmed cell death in cultured human serotonergic cells and rat neocortical neurons. Over the years it has been shown that MDMA alters...

Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent.

Life Sciences September 19, 2003 Stephen I Deutsch, Richard B Rosse, Eddie N Billingslea et al.

The ability of phencyclidine (PCP), a noncompetitive antagonist of NMDA receptor-mediated neurotransmission, to precipitate a schizophreniform psychosis in susceptible individuals is consistent with the hypothesized pathologic occurrence of NMDA receptor hypofunction in this disorder. Because the psychosis caused by PCP resembles schizophrenia in all of the relevant domains of psychopathology,...

Involvement of reduced acetylcholine release in Delta9-tetrahydrocannabinol-induced impairment of spatial memory in the 8-arm radial maze.

Life Sciences December 20, 2002 Kenichi Mishima, Nobuaki Egashira, Yoshiaki Matsumoto et al.

To clarify the mechanism by which Delta9-tetrahydrocannabinol, a major psychoactive component of marijuana, impairs spatial memory in the 8-arm radial maze in rats via the cholinergic system, we used two acetylcholinesterase inhibitors, physostigmine and tetrahydroaminoacridine. Moreover, we examined the effect of Delta9-tetrahydrocannabinol on acetylcholine release in the frontal cortex and...

Potentiation of DOM-induced stimulus control by fluoxetine and citalopram: role of pharmacokinetics.

Life Sciences August 2, 2002 Justin R Eckler, Mireille M Doat, R A Rabin et al.

The present investigation examined the interaction between 2,5-dimethoxy-4-methylamphetamine [DOM] and the selective serotonin reuptake inhibitor [SSRI] citalopram in rats trained with DOM [0.6 mg/kg; 75 min pretreatment time] as a discriminative stimulus. Pretreatment with citalopram at a dose of 1.0 mg/kg shifted the DOM dose response relationship to the left. Unlike previously tested SSRI's,...

Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats.

Life Sciences February 9, 2001 Andrew Harkin, Thomas J. Connor, J Mulrooney et al.

The substituted amphetamine 3,4 methylenedioxyamphetamine (MDA) is a popular recreational drug of abuse. Administration of MDA to experimental animals has been shown to induce damage to serotonergic axons and nerve terminals. However, there is a lack of information on whether these treatments can produce any long-term changes in behavioural performance particularly under stressful conditions....

Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists: a link between the glutamatergic and serotonergic hypotheses of schizophrenia.

Life Sciences December 8, 2000 Jerrold C Winter, Mireille M Doat, R A Rabin

The present investigation examined the interaction between 2,5-dimethoxy-4-methylamphetamine [DOM] and non-competitive NMDA antagonists in rats trained with DOM [0.6 mg/kg; 75 min pretreatment time] as a discriminative stimulus. Pretreatment with phencyclidine [PCP] at a dose of 3 mg/kg shifted the DOM dose-response relationship to the left. When a fixed dose of DOM [0.1 mg/kg] which by itself...

ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropylamine derivative, is a 5-HT2a and 5-HT2c receptor agonist.

Life Sciences November 17, 2000 Claudio Acuña-Castillo, C Scorza, Miguel Reyes-Parada et al. 3 citations

To assess the pharmacodynamic profile of ALEPH-2, a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties, Xenopus laevis oocytes were microinjected with either of the rat cRNA for the 5-HT2A or the 5-HT2C receptor. Concentration-response curves were obtained following the exposure of the oocytes to varying concentrations of either ALEPH-2 or 5-hydroxytryptamine...

Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro

Life Sciences June 1, 1998 Sabrina Giacomelli, Maura Palmery, Luca Romanelli et al. 51 citations

The hallucinogenic effects of lysergic acid diethylamide (LSD) have mainly been attributed to the interaction of this drug with the serotoninergic system, but it seems more likely that they are the result of the complex interactions of the drug with both the serotoninergic and dopaminergic systems. The aim of the present study was to investigate the functional actions of LSD at dopaminergic...

The effects of noribogaine and harmaline in rats trained with ibogaine as a discriminative stimulus.

Life Sciences 1997 Scott Helsley, R A Rabin, Jerrold C Winter 13 citations

In the present investigation, Fischer-344 rats were trained to discriminate 10.0 mg/kg of ibogaine from water using a pretreatment time of 60 minutes. Analysis of dose response data generated an ED50 of 4.6 mg/kg. The time course of the ibogaine (10.0 mg/kg) cue was also determined. The stimulus reached a maximum level of 94% ibogaine-appropriate responding at the 60-min pretreatment time. This...

Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration.

Life Sciences 1996 L B Hough, S M Pearl, Stanley D Glick 72 citations

The distribution of the putative anti-addictive substance ibogaine was measured in plasma, brain, kidney, liver and fat after ip and sc administration in rats. One hr after ip dosing (40 mg/kg), drug levels ranged from 106 ng/ml (plasma) to 11,308 ng/g (fat), with significantly higher values after sc administration of the same dose. Drug levels were 10-20 fold lower 12 hr after the same dose....

Facilitation of memory retrieval by the "anti-addictive" alkaloid, ibogaine.

Life Sciences 1996 Piotr Popik 18 citations

Anecdotal observations in humans indicate that indole alkaloid ibogaine may have anti-addictive properties. It has been suggested that the therapeutic action of ibogaine may depend upon facilitated access to the past experiences, purportedly influencing the initiation of drug addiction. To determine if ibogaine may facilitate memory retrieval, rats were trained in the Morris maze spatial...

Effects of ibogaine, and cocaine and morphine after ibogaine, on ventral tegmental dopamine neurons.

Life Sciences 1996 E D French, K Dillon, S F Ali 12 citations

Ibogaine, an indole containing alkaloid, has been shown to reduce the rate of injection of morphine and cocaine in self-administration protocols. Since morphine- and cocaine-induced modulation of dopamine release is impulse dependent and essential for their reinforcing effects, disruption of dopamine neuronal activity by ibogaine could explain its purported 'antiaddictive' properties....

Potentiation of LSD-induced stimulus control by fluoxetine in the rat.

Life Sciences 1996 David Fiorella, Scott Helsley, R A Rabin et al.

The present investigation examined the interaction between fluoxetine enantiomers and LSD in rats trained with LSD as a discriminative stimulus. The dose response relationships for LSD alone and in combination with either (+)- or (-)-fluoxetine were determined. In both instances, the LSD dose response relationship was shifted to the left. However, statistical significance was observed only for...

Ibogaine possesses a selective affinity for sigma 2 receptors.

Life Sciences 1995 R H Mach, C R Smith, S R Childers 145 citations

The alkaloid ibogaine is potentially useful to reduce craving for several drugs of abuse, but its mechanism of action is not known. In the current study, in vitro studies were conducted in order to determine the affinity of ibogaine for sigma receptors. Our results indicate that ibogaine has a relatively high affinity for sigma 2 receptors (Ki = 90.4 and 250 nM) and a significantly lower...

Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.

Life Sciences 1995 Deborah C. Mash, J K Staley, Michael H. Baumann et al. 108 citations

Ibogaine is a hallucinogenic indole with putative efficacy for the treatment of cocaine, stimulant and opiate abuse. The purported efficacy of ibogaine following single dose administrations has led to the suggestion that a long-acting metabolite of ibogaine may explain in part how the drug reduces craving for psychostimulants and opiates. We report here that 12-hydroxyibogamine, a primary...